SCOHIA PHARMA

Target: SCOHIA PHARMA, Inc.
Outline: R&D, manufacturing and sales of medical products
Total Investment: 10 billion JPY (INCJ 70.5%, Takeda 19.5%, MEDIPAL HD 10.0%)

INCJ

- Investment
- Dispatch of External Directors
- Management Support

Takeda Pharmaceutical Company Limited

- Investment
- Licensing of R&D products

Medipal Holdings Corporation

- Investment
- Domestic commercialization support

SCOHIA PHARMA Inc.

Promote R&D for new medicines

Key Areas: renal, metabolic and cardiovascular therapeutic areas

R&D Portfolio	Development Stage		
	Phase1	Phase2	Phase3
Early stage diabetic nephropathy/hypertension			
Obesity			
Diabetes			
5 other products that are in the preclinical or drug discovery stage			

Pharmaceutical Company

Licensing of R&D products

Pharmaceutical Company

・Contribution to the development of a bio-venture ecosystem through creation of a large-scale Biotech
・Promotion of domestic pharmaceutical companies' business portfolio conversion and opportunities to enhance international competitiveness
・Realize drug-discovery technology and development products hidden inside pharmaceutical companies as a strategy conversion and promote open innovation through strengthening external cooperation

Copyright © 2017 Innovation Network Corporation of Japan All Rights Reserved.